Adjusted EPS for Q2 rose to $0.86, beating analyst expectations
Company completed $2 bln accelerated share repurchase program
Result Drivers
Cardiovascular growth - Cardiovascular segment sales rose 8.3% yr/yr on a reported basis and 7.8% operationally, contributing to overall revenue growth
Strong emerging markets - Asia-Pacific sales grew 11.2% and Latin America/Canada sales rose 22.4% yr/yr, supporting overall company growth
Innovation and clinical milestones - Co cited investments in innovation and positive clinical trial results as supporting its growth strategy
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 28 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Boston Scientific Corp is $70.00, about 52% above its July 28 closing price of $46.06
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 18 three months ago
BSX•
